The invention provides a novel, general, and facile strategy for the creation of small molecules with high structural and stereochemical complexity. Aspects of the methods include ring system distortion reactions that are systematically applied to rapidly convert readily available natural products to structurally complex compounds with diverse molecular architectures. Through evaluation of chemical properties including fraction of sp.sup.3 carbons, ClogP, and the number of stereogenic centers, these compounds are shown to be significantly more complex and diverse than those in standard screening collections. This approach is demonstrated with natural products (gibberellic acid, adrenosterone, and quinine) from three different structural classes, and methods are described for the application of this strategy to any suitable natural product.

The invention provides a novel, general, and facile strategy for the creation of small molecules with high structural and stereochemical complexity. Aspects of the methods include ring system distortion reactions that are systematically applied to rapidly convert readily available natural products to structurally complex compounds with diverse molecular architectures. Through evaluation of chemical properties including fraction of sp.sup.3 carbons, ClogP, and the number of stereogenic centers, these compounds are shown to be significantly more complex and diverse than those in standard screening collections. This approach is demonstrated with natural products (gibberellic acid, adrenosterone, and quinine) from three different structural classes, and methods are described for the application of this strategy to any suitable natural product.

A method of increasing the rigidity of PIM homo- or co-polymers including repeating units containing at least one biscatechol monomer having a fused spiro-bisindane (SBI) ring system of Formula (I), the SBI ring system including a bicyclic spiro-carbon: (I) wherein each R.sup.1 can be the same or different, each R.sup.2 can be the same or different and wherein R.sup.1 and/or R.sup.2 are selected from any one or more of H; straight or branched, saturated or unsaturated lower C.sub.1-C.sub.6 alkyl groups, wherein the lower alkyl groups can include aromatic or non-aromatic ring structures; R.sup.3OR.sup.4, R.sup.3O(CO)R.sup.4, R.sup.3C(O)OR.sup.4, or R.sup.3OH, wherein each of R.sup.3 and R.sup.4 are the same or different and are selected from straight or branched, saturated or unsaturated lower C.sub.1-C.sub.6 alkyl groups; and R.sup.5 and R represent suitable linking monomers, wherein the linking monomers can be the same or different and are preferably selected from any one or more tetrahalo aromatic monomers; and wherein the method includes the step of introducing an intra-molecular lock between C1 and C2 of the biscatechol monomer of Formula (I).

Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.

Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.

The present specification relates to a heterocyclic compound represented by the following Chemical Formula 1 and an organic light emitting device including the same:

##STR00001## in Chemical Formula 1, R1 to R3 are the same as or different from each other, and each independently selected from the group consisting of hydrogen; deuterium; halogen; a cyano group; a substituted or unsubstituted C1 to C60 alkyl group; a substituted or unsubstituted C2 to C60 alkenyl group; a substituted or unsubstituted C2 to C60 alkynyl group; a substituted or unsubstituted C1 to C60 alkoxy group; a substituted or unsubstituted C3 to C60 cycloalkyl group; a substituted or unsubstituted C2 to C60 heterocycloalkyl group; a substituted or unsubstituted C6 to C60 aryl group; a substituted or unsubstituted C2 to C60 heteroaryl group; and a group represented by the following Chemical Formula 2, any one of R1 to R3 is the group represented by the following Chemical Formula 2, however, the remaining two are not the group represented by the following Chemical Formula 2, a and b are each independently an integer of 0 or 1, and satisfy a+b=1, m is one of integers of 1 to 4, when a or b is 0, n1 or n2 is each independently one of integers of 1 to 4, and when a or b is 1, n1 or n2 is each independently one of integers of 1 to 6,

##STR00002## in Chemical Formula 2, L1, L2 and L3 are the same as or different from each other, and each independently a single bond; a substituted or unsubstituted C6 to C60 arylene group; or a substituted or unsubstituted C2 to C60 heteroarylene group, Ar1 and Ar2 are the same as or different from each other, and each independently a substituted or unsubstituted C6 to C60 aryl group; or a substituted or unsubstituted C2 to C60 heteroaryl group, and p, q and r are the same as or different from each other, and each independently an integer of 0 to 3.

The present specification relates to a heterocyclic compound represented by the following Chemical Formula 1 and an organic light emitting device including the same:

##STR00001## in Chemical Formula 1, R1 to R3 are the same as or different from each other, and each independently selected from the group consisting of hydrogen; deuterium; halogen; a cyano group; a substituted or unsubstituted C1 to C60 alkyl group; a substituted or unsubstituted C2 to C60 alkenyl group; a substituted or unsubstituted C2 to C60 alkynyl group; a substituted or unsubstituted C1 to C60 alkoxy group; a substituted or unsubstituted C3 to C60 cycloalkyl group; a substituted or unsubstituted C2 to C60 heterocycloalkyl group; a substituted or unsubstituted C6 to C60 aryl group; a substituted or unsubstituted C2 to C60 heteroaryl group; and a group represented by the following Chemical Formula 2, any one of R1 to R3 is the group represented by the following Chemical Formula 2, however, the remaining two are not the group represented by the following Chemical Formula 2, a and b are each independently an integer of 0 or 1, and satisfy a+b=1, m is one of integers of 1 to 4, when a or b is 0, n1 or n2 is each independently one of integers of 1 to 4, and when a or b is 1, n1 or n2 is each independently one of integers of 1 to 6,

##STR00002## in Chemical Formula 2, L1, L2 and L3 are the same as or different from each other, and each independently a single bond; a substituted or unsubstituted C6 to C60 arylene group; or a substituted or unsubstituted C2 to C60 heteroarylene group, Ar1 and Ar2 are the same as or different from each other, and each independently a substituted or unsubstituted C6 to C60 aryl group; or a substituted or unsubstituted C2 to C60 heteroaryl group, and p, q and r are the same as or different from each other, and each independently an integer of 0 to 3.

Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.

Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.

Provided are a condensed cyclic compound and an organic light-emitting device including the same. The organic light-emitting device may include a first electrode, a second electrode, and an organic layer disposed between the first electrode and the second electrode. The organic layer may include the condensed cyclic compound represented by Formula 1:

##STR00001##

In Formula 1, rings A.sub.1, A.sub.2, and A.sub.3 may each be independently a C.sub.5-C.sub.60 carbocyclic group or a C.sub.2-C.sub.30 heterocyclic group, and n1 to n3 may each be independently 0 or 1, provided that the sum of n1, n2, and n3 is 1. In addition, the descriptions of X.sub.1, L.sub.1 to L.sub.9, a1 to a9, Ar.sub.1 to Ar.sub.6, b1 to b6, R.sub.1 to R.sub.3, and c1 to c3 are as defined in the present specification.